{"id":61979,"date":"2026-03-31T16:37:53","date_gmt":"2026-03-31T08:37:53","guid":{"rendered":"https:\/\/flcube.com\/?p=61979"},"modified":"2026-03-31T16:37:54","modified_gmt":"2026-03-31T08:37:54","slug":"aim-vaccine-plans-beijing-stock-exchange-ipo-to-strengthen-capital-base-and-expand-operations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61979","title":{"rendered":"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations"},"content":{"rendered":"\n<p><strong>AIM Vaccine Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6660:HKG\">HKG: 6660<\/a>), a China-based vaccine developer, has announced plans for an <strong>initial public offering (IPO)<\/strong> of <strong>40 million shares<\/strong> on the <strong>Beijing Stock Exchange<\/strong>. The offering is priced between <strong>RMB 3.0 and RMB 8.0 per share<\/strong>, with expected proceeds of <strong>at least RMB 40 million<\/strong> (USD 5.8 million) to bolster the company&#8217;s working capital and strategic growth initiatives.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-transaction-summary\">IPO Transaction Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>AIM Vaccine Co., Ltd. (HKG: 6660)<\/td><\/tr><tr><td><strong>Exchange<\/strong><\/td><td>Beijing Stock Exchange<\/td><\/tr><tr><td><strong>Shares Offered<\/strong><\/td><td>40 million<\/td><\/tr><tr><td><strong>Price Range<\/strong><\/td><td>RMB 3.0 \u2013 RMB 8.0 per share<\/td><\/tr><tr><td><strong>Minimum Proceeds<\/strong><\/td><td>RMB 40 million (USD 5.8 million)<\/td><\/tr><tr><td><strong>Primary Use of Proceeds<\/strong><\/td><td>Working capital supplementation<\/td><\/tr><tr><td><strong>Strategic Objectives<\/strong><\/td><td>Capital structure optimization, financial strength enhancement, business expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-capital-allocation\">Strategic Rationale &amp; Capital Allocation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Structure Optimization:<\/strong> Proceeds will improve the company&#8217;s debt-to-equity ratio and overall financial flexibility<\/li>\n\n\n\n<li><strong>Working Capital Enhancement:<\/strong> Increased liquidity to support day-to-day operations and inventory management<\/li>\n\n\n\n<li><strong>Financial Strength:<\/strong> Bolstered balance sheet to support research and development activities and manufacturing scale-up<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> Enhanced capital reserves to improve risk resistance capabilities in volatile market conditions<\/li>\n\n\n\n<li><strong>Growth Facilitation:<\/strong> Additional resources to accelerate business development and market expansion initiatives<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-analysis\">Market Context Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Beijing Stock Exchange Focus<\/strong><\/td><td>Platform specifically designed for innovative small and medium enterprises (SMEs)<\/td><\/tr><tr><td><strong>Vaccine Industry Dynamics<\/strong><\/td><td>Post-pandemic environment requires strong balance sheets for sustained R&amp;D investment<\/td><\/tr><tr><td><strong>Capital Requirements<\/strong><\/td><td>Vaccine development and manufacturing require significant working capital for raw materials and quality control<\/td><\/tr><tr><td><strong>Competitive Positioning<\/strong><\/td><td>Improved financial strength enhances ability to compete with larger domestic and international players<\/td><\/tr><tr><td><strong>Investor Appeal<\/strong><\/td><td>Access to China&#8217;s growing biotech investment ecosystem through dedicated SME exchange<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The Beijing Stock Exchange, established to support innovative SMEs, provides an ideal platform for AIM Vaccine to access growth capital while maintaining operational focus on its core vaccine development activities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-assessment\">Financial Impact Assessment<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Scale Expansion:<\/strong> Immediate increase in equity base from minimum RMB 40 million proceeds<\/li>\n\n\n\n<li><strong>Profitability Enhancement:<\/strong> Improved operational efficiency through optimized working capital management<\/li>\n\n\n\n<li><strong>Leverage Reduction:<\/strong> Potential to reduce reliance on debt financing for operational needs<\/li>\n\n\n\n<li><strong>Valuation Benchmark:<\/strong> Public listing establishes market valuation for future fundraising activities<\/li>\n\n\n\n<li><strong>Corporate Governance:<\/strong> Enhanced transparency and governance standards through public company requirements<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\">Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Listing Strategy:<\/strong> Maintains existing HKEX listing (6660) while accessing mainland Chinese capital markets<\/li>\n\n\n\n<li><strong>Growth Trajectory:<\/strong> Strengthened financial position supports pipeline advancement and commercial scale-up<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Beijing listing may improve access to domestic institutional investors and government support programs<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Enhanced capital base enables investment in next-generation vaccine technologies<\/li>\n\n\n\n<li><strong>Long-term Vision:<\/strong> Positions company for sustainable growth in China&#8217;s expanding vaccine market<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding AIM Vaccine&#8217;s IPO plans, capital allocation, and strategic objectives. Actual IPO terms, proceeds, and strategic outcomes may differ based on market conditions and regulatory approvals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033002325_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026033002325_c.\"><\/object><a id=\"wp-block-file--media-26ec9a02-d52b-4146-aff8-09f71e947f48\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033002325_c.pdf\">2026033002325_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026033002325_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-26ec9a02-d52b-4146-aff8-09f71e947f48\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61981,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[705,1401,72],"class_list":["post-61979","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-aim-vaccine","tag-hkg-6660","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an initial public offering (IPO) of 40 million shares on the Beijing Stock Exchange. The offering is priced between RMB 3.0 and RMB 8.0 per share, with expected proceeds of at least RMB 40 million (USD 5.8 million) to bolster the company&#039;s working capital and strategic growth initiatives.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61979\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations\" \/>\n<meta property=\"og:description\" content=\"AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an initial public offering (IPO) of 40 million shares on the Beijing Stock Exchange. The offering is priced between RMB 3.0 and RMB 8.0 per share, with expected proceeds of at least RMB 40 million (USD 5.8 million) to bolster the company&#039;s working capital and strategic growth initiatives.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61979\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T08:37:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T08:37:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3105.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61979#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61979\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations\",\"datePublished\":\"2026-03-31T08:37:53+00:00\",\"dateModified\":\"2026-03-31T08:37:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61979\"},\"wordCount\":464,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61979#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3105.webp\",\"keywords\":[\"AIM Vaccine\",\"HKG: 6660\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61979#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61979\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61979\",\"name\":\"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61979#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61979#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3105.webp\",\"datePublished\":\"2026-03-31T08:37:53+00:00\",\"dateModified\":\"2026-03-31T08:37:54+00:00\",\"description\":\"AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an initial public offering (IPO) of 40 million shares on the Beijing Stock Exchange. The offering is priced between RMB 3.0 and RMB 8.0 per share, with expected proceeds of at least RMB 40 million (USD 5.8 million) to bolster the company's working capital and strategic growth initiatives.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61979#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61979\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61979#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3105.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3105.webp\",\"width\":1080,\"height\":608,\"caption\":\"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61979#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations - Insight, China&#039;s Pharmaceutical Industry","description":"AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an initial public offering (IPO) of 40 million shares on the Beijing Stock Exchange. The offering is priced between RMB 3.0 and RMB 8.0 per share, with expected proceeds of at least RMB 40 million (USD 5.8 million) to bolster the company's working capital and strategic growth initiatives.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61979","og_locale":"en_US","og_type":"article","og_title":"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations","og_description":"AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an initial public offering (IPO) of 40 million shares on the Beijing Stock Exchange. The offering is priced between RMB 3.0 and RMB 8.0 per share, with expected proceeds of at least RMB 40 million (USD 5.8 million) to bolster the company's working capital and strategic growth initiatives.","og_url":"https:\/\/flcube.com\/?p=61979","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-31T08:37:53+00:00","article_modified_time":"2026-03-31T08:37:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3105.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61979#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61979"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations","datePublished":"2026-03-31T08:37:53+00:00","dateModified":"2026-03-31T08:37:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61979"},"wordCount":464,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61979#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3105.webp","keywords":["AIM Vaccine","HKG: 6660","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61979#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61979","url":"https:\/\/flcube.com\/?p=61979","name":"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61979#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61979#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3105.webp","datePublished":"2026-03-31T08:37:53+00:00","dateModified":"2026-03-31T08:37:54+00:00","description":"AIM Vaccine Co., Ltd. (HKG: 6660), a China-based vaccine developer, has announced plans for an initial public offering (IPO) of 40 million shares on the Beijing Stock Exchange. The offering is priced between RMB 3.0 and RMB 8.0 per share, with expected proceeds of at least RMB 40 million (USD 5.8 million) to bolster the company's working capital and strategic growth initiatives.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61979#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61979"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61979#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3105.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3105.webp","width":1080,"height":608,"caption":"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61979#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3105.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61979"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61979\/revisions"}],"predecessor-version":[{"id":61982,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61979\/revisions\/61982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61981"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}